Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies

Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

31-Oct-2024

Merck announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.

The investment represents a critical step in the company’s ongoing growth journey to partner with new and existing clients as they advance their drug development pipelines. With additional capacity and by scaling utilities and enhancing Process and Analytical Development (PAD) labs, Merck will provide industry-leading support for early-stage and commercial bioconjugates. The company’s goal is to ensure clients can bring their innovations to market more effectively and with shorter turnaround times.

“We are shaping tomorrow’s cancer care, today. With this investment, we are not just enhancing our capabilities; we are investing in our clients’ success by accelerating innovation and development to ultimately deliver novel therapies to patients more quickly,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck. “ADCs represent a transformative approach to oncology, enabling targeted therapies that minimize damage to healthy tissues. As the market for this novel modality grows and the medical community adopts them as first-line treatments, it may mean that fewer patients need invasive treatments like chemotherapy and radiation that cause significant side effects.”

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Simtra BioPharma Solutions - Parsippany, USA

Simtra BioPharma Solutions - Parsippany, USA

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

European Medicines Agency recommends that Linoladiol N and Linoladiol HN remain available - Benefits continue to outweigh risks with new restrictions

Advises on compassionate use of a new combination therapy for chronic hepatitis C - Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease

EMA recommends approval of new treatment for platinum-resistant ovarian cancer - Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond

EMA endorses revised policy on handling of declarations of interests

Recommendation against combined use of medicines affecting the renin-angiotensin system

UK Agency’s Update on “Three-Person IVF” Leaves Safety Questions Unresolved - Parliamentary Vote Would be Premature, Says Public Interest Group

EMA to relocate to Amsterdam - Working with Dutch government to ensure successful move by end of March 2019